Karsten Voermann - 08 Mar 2023 Form 4 Insider Report for GoodRx Holdings, Inc. (GDRX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
09 Mar 2023, 18:59:12 UTC
Prior SEC filing
12 Dec 2022
Next SEC filing
12 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Gracye Cheng, as Attorney-in-Fact for Karsten Voermann

Key filing fact

Karsten Voermann filed Form 4 for GoodRx Holdings, Inc. (GDRX) on 09 Mar 2023.

Key facts

  • This page summarizes Karsten Voermann's Form 4 filing for GoodRx Holdings, Inc. (GDRX).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 09 Mar 2023, 18:59.

Change

  • Previous filing in this sequence was filed on 12 Dec 2022.
  • Current net transaction value: -$95,684.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GDRX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares
+54,064
Change %
+145%
Price
Shares after
91,458
Date
08 Mar 2023
Ownership
Direct
Footnotes
F1
GDRX transaction

Class A Common Stock

Tax liability

Transaction value
$95,684
Shares
-17,397
Change %
-19%
Price
$5.50
Shares after
74,061
Date
08 Mar 2023
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GDRX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-54,064
Change %
-6.7%
Price
$0.000000
Shares after
756,896
Date
08 Mar 2023
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
54,064
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

Footnote F2

The restricted stock unit award vested as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .